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ABSTRACT 
     Although most infections begin at a mucosal surface and may be prevented by 
effective vaccine stimulation of the local mucosal immune system, there are so far only 
a few mucosal vaccines available for human use. This thesis spans several areas that are 
important for future development of mucosal vaccines.  
     Future vaccine development will depend in part on the efficient production of 
recombinant antigens produced in bacterial expression systems. To avoid current 
problems with the use of antibiotics to maintain expression plasmids, an E. coli strain 
capable of producing recombinant proteins using vectors maintained without the need 
antibiotic was generated. The method is based on deletion of the essential lgt gene 
encoding a (pro)lipoprotein glyceryl transferase and complementing it with an 
expression vector carrying the non-homologous lgt gene from V. cholerae. A similar V. 
cholerae lgt-deleted strain was also constructed using the E. coli lgt gene for 
complementation. The strains had similar growth and production characteristics as their 
wild-type counterparts but maintained their expression plasmids without the need for 
antibiotics. The system was used to express two recombinant vaccine proteins, cholera 
toxin B subunit and a fusion protein for vaccination against atherosclerosis. 
     In the development of mucosal vaccines, it is often important to enhance immune 
responses using adjuvants, since most mucosally administered antigens are poorly 
immunogenic. Cholera toxin (CT) is the most powerful mucosal adjuvant known but is 
too toxic for human use. A mutated CT derivative (mmCT) was constructed and 
expressed in an engineered strain of V. cholerae. mmCT induced 1000 times less cAMP 
than native CT in a mouse thymocyte toxicity assay, was non-toxic in an infant mouse 
model and yet retained similar adjuvant properties as native CT. We suggest that mmCT 
is a promising candidate for use in future mucosal vaccines.  
     The mode of adjuvant action of mmCT and native CT was investigated using human 
and mouse antigen-presenting cells, which are primary target cells for adjuvants. Both 
molecules were found to activate cyclic AMP/protein kinase A-dependent canonical 
NF-κB signaling associated with inflammasome activation. The activation of these 
pathways was found to induce expression of two immunomodulatory proteins, THSB1 
and ITGB1, as well as increased expression and activation of IL-1β, a cytokine which 
has been shown to play an important role for the adjuvant action of CT and mmCT. 
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